BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32738501)

  • 1. Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation.
    Bondeelle L; Chevret S; Hurabielle C; Samy L; Goletto T; Costantini A; Sicre de Fontbrune F; Michonneau D; Socié G; Tazi A; Bouaziz JD; Bergeron A
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2115-2120. PubMed ID: 32738501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.
    Gazourian L; Rogers AJ; Ibanga R; Weinhouse GL; Pinto-Plata V; Ritz J; Soiffer RJ; Antin JH; Washko GR; Baron RM; Ho VT
    Am J Hematol; 2014 Apr; 89(4):404-9. PubMed ID: 24375545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of pulmonary function test before transplantation for chronic pulmonary graft-versus-host-disease after allogeneic hematopoietic stem cell transplantation.
    Yang L; Cheng J; Li F; Qian R; Zhang X; Jin S; He X; Xu T; Hu X; Ma X; Chen J; Zhu Y; Chen F
    BMC Pulm Med; 2022 Dec; 22(1):473. PubMed ID: 36510158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inert Gas Washout in Bronchiolitis Obliterans Following Hematopoietic Cell Transplantation.
    Nyilas S; Baumeler L; Tamm M; Halter JP; Savic S; Korten I; Meyer A; Singer F; Passweg JR; Latzin P; Stolz D
    Chest; 2018 Jul; 154(1):157-168. PubMed ID: 29275133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
    Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
    JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation.
    Zhao Y; OuYang G; Shi J; Luo Y; Tan Y; Yu J; Fu H; Lai X; Liu L; Huang H
    Front Pharmacol; 2021; 12():668825. PubMed ID: 34262450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of Lower Respiratory Tract Infections and Community-Acquired Respiratory Viruses in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation: A Retrospective Cohort Study.
    Epstein DJ; Liang EC; Sharifi H; Lai YK; Arai S; Graber-Naidich A; Sundaram V; Nelson J; Hsu JL
    Transplant Cell Ther; 2022 Oct; 28(10):705.e1-705.e10. PubMed ID: 35872303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung hyperinflation quantitated by chest CT in children with bronchiolitis obliterans syndrome following allogeneic hematopoietic cell transplantation.
    Moutafidis D; Gavra M; Golfinopoulos S; Oikonomopoulou C; Kitra V; Woods JC; Kaditis AG
    Clin Imaging; 2021 Jul; 75():97-104. PubMed ID: 33515927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant.
    Cheng GS; Storer B; Chien JW; Jagasia M; Hubbard JJ; Burns L; Ho VT; Pidala J; Palmer J; Johnston L; Mayer S; Crothers K; Pusic I; Lee SJ; Williams KM
    Ann Am Thorac Soc; 2016 Nov; 13(11):1932-1939. PubMed ID: 27513368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
    Mohseni R; Mahdavi Sharif P; Behfar M; Modaresi MR; Shirzadi R; Mardani M; Jafari L; Jafari F; Nikfetrat Z; Hamidieh AA
    Stem Cell Res Ther; 2023 Sep; 14(1):256. PubMed ID: 37726865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation.
    Alkhunaizi M; Patel B; Bueno L; Bhan N; Ahmed T; Arain MH; Saliba R; Rondon G; Dickey BF; Bashoura L; Ost DE; Li L; Wang S; Shpall E; Champlin RE; Mehta R; Popat UR; Hosing C; Alousi AM; Sheshadri A
    Transplant Cell Ther; 2023 Mar; 29(3):204.e1-204.e7. PubMed ID: 36503180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
    Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
    Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease.
    Chien JW; Duncan S; Williams KM; Pavletic SZ
    Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S106-14. PubMed ID: 19896545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease.
    Brownback KR; Thomas LA; McGuirk JP; Ganguly S; Streiler C; Abhyankar S
    Lung; 2017 Dec; 195(6):781-788. PubMed ID: 28894914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
    Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
    Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical analysis of bronchiolitis obliterans syndrome after haplo- hematopoietic stem cell transplantation].
    Zhuang J; Gu B; Ke P; Liu YJ; Wu XJ; Xue SL; Hu XH; He XF; Ma X; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):404-410. PubMed ID: 31207706
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation.
    Zhang X; Zhao X; Shen Y; Shi Y; Zhang L; Hao M; Zhao F; Zhang R; Wei J; Feng S; He Y; Jiang E; Han M
    Front Pharmacol; 2022; 13():916472. PubMed ID: 35865938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
    White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
    Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced sclerosis of the chest wall skin secondary to chronic graft-versus-host disease: a case with severe restrictive lung defect.
    Ödek Ç; Kendirli T; İleri T; Yaman A; Fatih Çakmakli H; Ince E; İnce E; Ertem M
    J Pediatr Hematol Oncol; 2014 Oct; 36(7):e473-5. PubMed ID: 24577553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.